

The Department of Vermont Health Access Clinical Criteria

Subject: Cystic Fibrosis Gene Test

Last Review: January 28, 2020*

Past Revisions: May 10, 2016, June 15, 2015 and July 6, 2017.

***Please note: Most current content changes will be highlighted in yellow.**

Description of Service or Procedure

Cystic fibrosis (CF) is an autosomal recessive disorder (i.e. an individual **must** inherit a copy of a genetic variant from each parent in order to have the disease). If an individual inherits only one copy, she will not inherit the actual disease but will be a carrier and could pass the disease to her children. If both parents carry the defective gene for CF, there is a 25% chance of producing a child with CF, a 50% chance the child will carry the CF gene but not have CF and a 25% chance the child will not carry the gene and not have CF. Approximately 70,000 individuals are affected by CF worldwide.

The CF gene test uses a blood sample or cells from inside the cheek for DNA analysis to identify the presence of a genetically altered cystic fibrosis transmembrane conductance regulator gene.

Prevalence of CF varies by ethnicity with Caucasians having the highest rates of about 1 in every 3,000 births.

Newborn screening for CF is done in the first 2 or 3 days after birth. If screening is positive, a sweat test is performed to confirm the diagnosis.

The severity of clinical symptoms that may occur in individuals with CF cannot be definitively predicted on cystic fibrosis transmembrane conductance regulator gene variant testing alone.

Genetic testing for CF is not available for the general public.

Disclaimer

Coverage is limited to that outlined in Medicaid Rule or Health Care Administrative Rules that pertains to the beneficiary's aid category. Prior Authorization (PA) is only valid if the beneficiary is eligible for the applicable item or service on the date of service.



Medicaid Rule

Health Care Administrative Rules and can be found at <https://humanservices.vermont.gov/rules-policies/health-care-rules/health-care-administrative-rules-hcar>

Medicaid Rules

- 7102.2 Prior Authorization Determination
- 7103 Medical Necessity

Coverage Position

Cystic fibrosis testing may be covered for beneficiaries:

- When the CF gene test is prescribed by a licensed medical provider, enrolled in the Vermont Medicaid program, operating within their scope of practice as described in their Vermont State Practice Act, who is knowledgeable regarding the CF gene test and who provides medical care to the beneficiary AND
- When the clinical criteria below are met.

Coverage Criteria

Cystic fibrosis testing may be covered for beneficiaries who:

1. Have clinical symptoms characteristic of CF (pancreatic insufficiency, lung function abnormalities and high sweat chloride test)
2. Have a family history of CF
3. Are couples planning a pregnancy and wish to know if either is a CF carrier
4. Are reproductive partners of persons with CF
5. Desire a prenatal diagnosis to identify a fetus or embryo with CF for purposes of post-delivery care of the newborn.

Considerations: Providers requesting this test should provide pre- and post-test genetic counseling for the beneficiary and family, if applicable.

Early and Periodic Screening, Diagnostic and Treatment (EPSDT) exception: Vermont Medicaid will provide comprehensive services and furnish all Medicaid coverable, appropriate, and medically necessary services needed to correct and ameliorate health conditions for Medicaid members under age 21.

Clinical guidelines for repeat service or procedure

The same criteria apply as for the initial use.

Type of service or procedure not covered (this list may not be all inclusive)

Cystic fibrosis testing for the general public is not covered.

References

About Cystic Fibrosis. (2014). Retrieved February 27, 2017, from:

<https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/>

Bobadilla, J. L., Macek, M., Fine, J. P., Farrell, P. M. (2002). *Cystic fibrosis: A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening*.

Retrieved February 27, 2017, from:

<http://onlinelibrary.wiley.com/doi/10.1002/humu.10041/pdf>

Castellani, C., Picci, L., Tamanini, A., Girardi, P., Rizzotti, P., & Assael, B. (2009). Association between carrier screening and incidence of cystic fibrosis. *Journal of the American Medical Association*, 302(23). Retrieved February 27, 2017, from:

http://www.google.com/url?sa=t&ret=j&q=&esrc=s&source=web&cd=3&ved=0CCcQFjAC&url=http%3A%2F%2Fwww.researchgate.net%2Fprofile%2FBaroukh_Assael%2Fpublication%2F40686773_Association_between_carrier_screening_and_incidence_of_cystic_fibrosis%2Flinks%2F0c960520ca5ef309d500000.pdf&ei=WzaVMHBMoeWgwSWmoLABw&usg=AFQjCNET7QRyQzeMWXDR5dVBhieRELEShQ&bvm=bv.85464276,d.eXY

Hayes, Inc. Hayes GTE Report. *Cystic Fibrosis Transmembrane Regulator (CFTR) Testing for Cystic Fibrosis*. Landsdale, PA: Hayes, Inc.; May 30, 2013.

Farrell, P., Rosenstein, B., White, T., Accurso, F., Castellani, C., Cutting, G. et al. (2008). Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. *National Center for Biotechnology Information*, 153(2). Retrieved February 27, 2017, from:

[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810958/?log\\$=activity](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810958/?log$=activity)

McKone, E. F., Amerson, S. S., Edwards, K. L., & Aitken, M. L. (2003). Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. *The Lancet*, 361(9370). Retrieved, February 27, 2017 from: <http://www.ncbi.nlm.nih.gov/pubmed/12767731>

National Human Genome Research Institute. (2013). *Learning about cystic fibrosis*. Retrieved February 27, 2017 from:

<http://www.genome.gov/10001213>

Rohlf, E. M., Zhou, Z., Heim, R. A., Nagan, N., Rosenblum, L. S., Flynn, K. et al. (2011). Cystic fibrosis carrier testing in an ethnically diverse US population. *National Center for Biotechnology Information*, 57(6). Retrieved February 27, 2017, from: <http://www.clinchem.org/content/57/6/841.long>

U.S. National Library of Medicine. Cystic Fibrosis. (2012). *Genetics home reference. Your guide to understanding genetic conditions. Cystic fibrosis*. Retrieved February 27, 2017, from:

<http://ghr.nlm.nih.gov/condition/cystic-fibrosis>

The American Congress of Obstetricians and Gynecologists (ACOG) (2011). Cystic fibrosis – prenatal screening and diagnosis. *Obstetrics and Gynecology*, 171. Retrieved February 27, 2017, from:

<http://www.acog.org/Patients/FAQs/Cystic-Fibrosis-Prenatal-Screening-and-Diagnosis>

The American Congress of Obstetricians and Gynecologists (ACOG) (2011). Update on carrier screening for cystic fibrosis, *Committee on Genetics*, 486. Retrieved February 11, 2016, from:
<http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Genetics/Updateon-Carrier-Screening-for-Cystic-Fibrosis>

This document has been classified as public information.